Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer

Darryl T. Martin, Jill M. Steinbach, Jingchun Liu, Shogo Shimizu, Hristos Kaimakliotis, Marcia A. Wheeler, Adam B. Hittelman, W. Mark Saltzman, Robert M. Weiss

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Penetration of the bladder permeability barrier (BPB) is a major challenge when treating bladder diseases via intravesical delivery. To increase transurothelial migration and tissue and tumor cell uptake, poly (lactic-co-glycolic acid; PLGA) nanoparticles (NP) were modified by addition of a low molecular weight (2.5 or 20 kDa) positively charged mucoadhesive polysaccharide, chitosan, to the NP surface. In designing these NPs, we balanced the adhesive properties of chitosan with the release and bioactivity of the siRNA. Chitosan-functionalized NPs demonstrated increased binding to and uptake in intravesically instilled mouse bladders and human ureter at 10 times the level of unmodified NPs. Furthermore, we extended the bioactivity of survivin siRNA in vitro for up to 9 days and demonstrated a decrease in proliferation when using chitosan-modified NPs relative to unmodified NPs. In addition, treatment of xenograft tumors with chitosan-modified NPs that encapsulate survivin siRNA (NP-siSUR-CH2.5) resulted in a 65% reduction in tumor volume and a 75% decrease in survivin expression relative to tumors treated with blank chitosan NPs (NP-Bk-CH2.5). Our lowmolecular weight chitosan delivery system has the capacity to transport large amounts of siRNA across the urothelium and/or to the tumor site, thus increasing therapeutic response.

Original languageEnglish (US)
Pages (from-to)71-81
Number of pages11
JournalMolecular Cancer Therapeutics
Volume13
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Chitosan
Urinary Bladder Neoplasms
Nanoparticles
Small Interfering RNA
Neoplasms
Urinary Bladder
Urinary Bladder Diseases
Urothelium
Ureter
Tumor Burden
Heterografts
Adhesives
Polysaccharides
Permeability
Molecular Weight
Weights and Measures

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer. / Martin, Darryl T.; Steinbach, Jill M.; Liu, Jingchun; Shimizu, Shogo; Kaimakliotis, Hristos; Wheeler, Marcia A.; Hittelman, Adam B.; Mark Saltzman, W.; Weiss, Robert M.

In: Molecular Cancer Therapeutics, Vol. 13, No. 1, 01.2013, p. 71-81.

Research output: Contribution to journalArticle

Martin, Darryl T. ; Steinbach, Jill M. ; Liu, Jingchun ; Shimizu, Shogo ; Kaimakliotis, Hristos ; Wheeler, Marcia A. ; Hittelman, Adam B. ; Mark Saltzman, W. ; Weiss, Robert M. / Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer. In: Molecular Cancer Therapeutics. 2013 ; Vol. 13, No. 1. pp. 71-81.
@article{682628a757784abda9de84d9544a7eb0,
title = "Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer",
abstract = "Penetration of the bladder permeability barrier (BPB) is a major challenge when treating bladder diseases via intravesical delivery. To increase transurothelial migration and tissue and tumor cell uptake, poly (lactic-co-glycolic acid; PLGA) nanoparticles (NP) were modified by addition of a low molecular weight (2.5 or 20 kDa) positively charged mucoadhesive polysaccharide, chitosan, to the NP surface. In designing these NPs, we balanced the adhesive properties of chitosan with the release and bioactivity of the siRNA. Chitosan-functionalized NPs demonstrated increased binding to and uptake in intravesically instilled mouse bladders and human ureter at 10 times the level of unmodified NPs. Furthermore, we extended the bioactivity of survivin siRNA in vitro for up to 9 days and demonstrated a decrease in proliferation when using chitosan-modified NPs relative to unmodified NPs. In addition, treatment of xenograft tumors with chitosan-modified NPs that encapsulate survivin siRNA (NP-siSUR-CH2.5) resulted in a 65{\%} reduction in tumor volume and a 75{\%} decrease in survivin expression relative to tumors treated with blank chitosan NPs (NP-Bk-CH2.5). Our lowmolecular weight chitosan delivery system has the capacity to transport large amounts of siRNA across the urothelium and/or to the tumor site, thus increasing therapeutic response.",
author = "Martin, {Darryl T.} and Steinbach, {Jill M.} and Jingchun Liu and Shogo Shimizu and Hristos Kaimakliotis and Wheeler, {Marcia A.} and Hittelman, {Adam B.} and {Mark Saltzman}, W. and Weiss, {Robert M.}",
year = "2013",
month = "1",
doi = "10.1158/1535-7163.MCT-13-0502",
language = "English (US)",
volume = "13",
pages = "71--81",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer

AU - Martin, Darryl T.

AU - Steinbach, Jill M.

AU - Liu, Jingchun

AU - Shimizu, Shogo

AU - Kaimakliotis, Hristos

AU - Wheeler, Marcia A.

AU - Hittelman, Adam B.

AU - Mark Saltzman, W.

AU - Weiss, Robert M.

PY - 2013/1

Y1 - 2013/1

N2 - Penetration of the bladder permeability barrier (BPB) is a major challenge when treating bladder diseases via intravesical delivery. To increase transurothelial migration and tissue and tumor cell uptake, poly (lactic-co-glycolic acid; PLGA) nanoparticles (NP) were modified by addition of a low molecular weight (2.5 or 20 kDa) positively charged mucoadhesive polysaccharide, chitosan, to the NP surface. In designing these NPs, we balanced the adhesive properties of chitosan with the release and bioactivity of the siRNA. Chitosan-functionalized NPs demonstrated increased binding to and uptake in intravesically instilled mouse bladders and human ureter at 10 times the level of unmodified NPs. Furthermore, we extended the bioactivity of survivin siRNA in vitro for up to 9 days and demonstrated a decrease in proliferation when using chitosan-modified NPs relative to unmodified NPs. In addition, treatment of xenograft tumors with chitosan-modified NPs that encapsulate survivin siRNA (NP-siSUR-CH2.5) resulted in a 65% reduction in tumor volume and a 75% decrease in survivin expression relative to tumors treated with blank chitosan NPs (NP-Bk-CH2.5). Our lowmolecular weight chitosan delivery system has the capacity to transport large amounts of siRNA across the urothelium and/or to the tumor site, thus increasing therapeutic response.

AB - Penetration of the bladder permeability barrier (BPB) is a major challenge when treating bladder diseases via intravesical delivery. To increase transurothelial migration and tissue and tumor cell uptake, poly (lactic-co-glycolic acid; PLGA) nanoparticles (NP) were modified by addition of a low molecular weight (2.5 or 20 kDa) positively charged mucoadhesive polysaccharide, chitosan, to the NP surface. In designing these NPs, we balanced the adhesive properties of chitosan with the release and bioactivity of the siRNA. Chitosan-functionalized NPs demonstrated increased binding to and uptake in intravesically instilled mouse bladders and human ureter at 10 times the level of unmodified NPs. Furthermore, we extended the bioactivity of survivin siRNA in vitro for up to 9 days and demonstrated a decrease in proliferation when using chitosan-modified NPs relative to unmodified NPs. In addition, treatment of xenograft tumors with chitosan-modified NPs that encapsulate survivin siRNA (NP-siSUR-CH2.5) resulted in a 65% reduction in tumor volume and a 75% decrease in survivin expression relative to tumors treated with blank chitosan NPs (NP-Bk-CH2.5). Our lowmolecular weight chitosan delivery system has the capacity to transport large amounts of siRNA across the urothelium and/or to the tumor site, thus increasing therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=84892569827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892569827&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-0502

DO - 10.1158/1535-7163.MCT-13-0502

M3 - Article

C2 - 24222663

AN - SCOPUS:84892569827

VL - 13

SP - 71

EP - 81

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -